Immunotherapy plus TACE for liver cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a new immunotherapy drug (GKL-006) combined with a standard treatment called TACE (which blocks blood flow to the tumor) for people with liver cancer that cannot be removed by surgery. The goal is to see if adding this drug helps shrink tumors more than TACE alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have been diagnosed with liver cancer (hepatocellular carcinoma) that cannot be removed by surgery.
- Your cancer is at a stage called CNLC II to IIIa (your doctor can confirm this).
- You have at least one tumor that can be measured on a scan.
- Your liver function is good enough (Child-Pugh class A or B).
- You are able to perform daily activities (ECOG score 0-2).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of TACE (a procedure that blocks blood supply to the tumor) plus three immunotherapy drugs (sintilimab, bevacizumab, ipilimumab) for people with advanced liver cancer that cannot be removed by surgery. The goal is to see if this combination works better than TACE alone.
This trial is for people with advanced liver cancer (HCC) that has spread outside the liver. It tests whether combining a TACE procedure with immunotherapy and anti-angiogenesis drugs can improve outcomes. You must not have had prior systemic therapy and must have received TACE in a specific time window around starting these drugs.
This study tests a combination of a liver-directed treatment (TACE) with two immunotherapy drugs and bevacizumab for patients with liver cancer that cannot be surgically removed but has not spread outside the liver. The goal is to see if this approach can shrink tumors and improve outcomes.
This trial tests a combination of an immunotherapy drug (QL1706) and a liver-directed procedure (TACE) before and after surgery for people with liver cancer that is larger or more advanced than the usual transplant criteria. The goal is to see if this approach can help shrink the tumor and improve outcomes.
This trial tests a new immunotherapy drug (ivonescimab) combined with TACE (a procedure that blocks blood flow to the tumor) for people with liver cancer that cannot be surgically removed. It aims to see if adding the immunotherapy can help control the cancer better than TACE alone.
This study tests combining TACE (a procedure to block the tumor's blood supply) with immunotherapy drugs for liver cancer that has not spread outside the liver. It is for people who have not had any prior treatment for their liver cancer and are healthy enough for TACE.
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.